US FDA warns Novo for second time about misleading drug advertising
US FDA warns Novo for second time about misleading drug advertising
ReutersTue, March 3, 2026 at 10:23 PM UTC
0
A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023. REUTERS/Lee Smith
March 3 (Reuters) - The U.S. Food and Drug Administration has told Novo Nordisk to stop running a consumer ad for its blockbuster diabetes drug Ozempic, saying the commercial makes false and misleading claims about what the drug can do.
It is the second time in less than a month that the FDA has warned the Danish drugmaker for deceptive advertising.
The latest letter, dated February 26, takes aim at an ad for Ozempic, the company's flagship diabetes injection.
Advertisement
The first warning letter, issued on February 5, was about a TV spot for Wegovy, Novo's weight-loss pill.
Novo Nordisk did not immediately respond to Reuters' request for comment.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shinjini Ganguli)
Source: “AOL Breaking”
